In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Nanosphere brings in $35.7mm through follow-on

Executive Summary

Nanosphere (nanotechnology-based molecular diagnostics) netted $35.7mm through the follow-on public offering of 5.4mm common shares (including the overallotment) at $7 each. The company is developing tests with applications in oncology, infectious disease, cardiovascular disease, neurological conditions, and autoimmune disorders.
Deal Industry
  • Biotechnology
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register